Eli Lilly refocuses strategy on obesity and chronic disease amid 70th anniversary

Eli Lilly's international president highlights the company's strategic pivot toward obesity and chronic disease treatments, emphasizing public-private partnerships. This signals continued corporate focus on high-growth therapeutic areas, though no new product or financial details were disclosed.